Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,015 | $881 | $2,010 | $790,565 |
| - Cash | $6,070 | $7,322 | $8,931 | $3,710 |
| + Debt | $0 | $0 | $7,249 | $7,386 |
| Enterprise Value | -$5,055 | -$6,440 | $327 | $794,241 |
| Revenue | $0 | $0 | $0 | $725 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $461 |
| % Margin | – | – | – | 63.5% |
| EBITDA | -$215 | -$1,801 | -$1,458 | -$8,439 |
| % Margin | – | – | – | -1,163.3% |
| Net Income | -$923 | $5,433 | -$2,260 | -$9,273 |
| % Margin | – | – | – | -1,278.4% |
| EPS Diluted | -0.022 | -1.29 | -9.37 | -0.13 |
| % Growth | 98.3% | 86.2% | -7,107.7% | – |
| Operating Cash Flow | -$1,134 | -$3,007 | -$1,660 | $965 |
| Capital Expenditures | $0 | $0 | $0 | -$5 |
| Free Cash Flow | -$1,134 | -$3,007 | -$1,660 | $960 |